NASH

Incorporating the Patient’s Voice in NASH Clinical Trials

October 13, 2023

Non-Invasive Approaches to NAFLD/NASH Drug Development

June 27, 2023

Time for Change in NASH: How Non-Invasive Biomarkers are Driving a Paradigm Shift in Clinical Trials and Clinical Care

October 27, 2022

NASH Populations with Cirrhosis: Drug Development Challenges and Solutions

February 16, 2022

Reliability of Liver Biopsies in NASH Clinical Studies: What is Known So Far? What’s Next?

November 09, 2020
Clinical Trial News

NAFLD & NASH Clinical Trials: Viking Therapeutics Reports Positive Phase II Trial Data

In Light of NASH: How to Optimize Your Liver Biopsy Results

September 15, 2020

Expediting NASH Clinical Trials and Biomarker Research: NASH PASS®, a Growing Patient Registry Platform

September 15, 2020

NASH Clinical Development During the COVID-19 (Coronavirus) Pandemic

May 28, 2020

Non-Invasive Evaluation of Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis: Present and Future

March 11, 2020

Imaging for NAFLD/NASH: Current State and Future Trends

September 10, 2019

NASH Clinical Drug Development: Imaging the Liver and Beyond

October 22, 2019

Forging the Way Ahead to Better Drug Development for NASH Patients

July 24, 2019
Blogs

Six of the Latest NASH/NAFLD Webinars

Think Enrolling Your NASH Trial Will Be Easy? Think Again.

May 22, 2019
Clinical Trial News

Multi-Dose NASH Clinical Trial Underway for Durect’s DUR-928